Streetwise Reports' Article Archives — November 2023 back to current month (14)

Biotech Announces New Responder in Breast Cancer Trail (11/30/2023)

Recently, BriaCell Therapeutics Corp. announced a new exceptional responder in its Phase 2 study evaluating the company's off-the-shelf personalized immunotherapy, noted H.C. Wainwright analyst Emily Bodnar.


Biotech Receives First Approval; Drug Now Available (11/28/2023)

Recently, SpringWorks Therapeutics Inc. announced FDA approval of OGSIVEO (nirogacestat) for treating progressing desmoid tumors (DT) in adult patients based on Phase 3 DeFi trial results, noted H.C. Wainwright & Co. analysts Robert Burns and Dr. Raghuram Selvaraju.


Encouraging Early Data For Biotech's Cancer Therapies (11/21/2023)

In a recent corporate update, Purple Biotech Ltd. reported positive interim Phase 1/2 data for NT219 and accelerated enrollment for CM24, noted H.C. Wainwright analyst Emily Bodnar.


Strong Early Launch Metrics for Biotech's Skin Disease Drug (11/20/2023)

Oren Livnat of H.C. Wainwright & Co. sees over 240% upside potential for Verrica Pharmaceuticals based on the early commercial success of its recently launched skin disease treatment.


Arizona Biotech Advances Multiple Cell Therapies (11/16/2023)

Roth MKM has a US$30 price target on this biotech company based on progress across its regenerative medicine pipeline, including upcoming Phase 1/2 data.


Massachusetts Biotech Advances Novel Cytokine Therapies (11/15/2023)

Wedbush sees over 300% upside for Werewolf stock based on early clinical success for its PREDATOR platform and pipeline, according to a WedBush research note.


Massachusetts Biotech Presents Catalysts Into 2024 (11/08/2023)

Cambridge, Massachusetts-based iTeos Therapeutics presented multiple upcoming catalysts into 2024 after reporting Q3 results, noted Wedbush analyst Dr. David Nierengarten.


Texas Biotech Exceeds Alzheimer's Trial Enrollment Target (11/08/2023)

This Texas-based biotech company's enrollment in its two pivotal Phase 3 trials evaluating lead drug candidate simufilam for Alzheimer's disease surpassed initial enrollment targets, noted H.C. Wainwright analyst Vernon Bernardino.


Expert Shares Thoughts on Six Stocks (11/07/2023)

Chris Temple of The National Investors shares a detailed report on stocks from the life science to the energy sector to tell you which he believes are Buys and which you should sell.


Biopharma Acquires Royalty on Approved Diabetes Drug (11/03/2023)

This is one of the California-based company's many transactions resulting from its royalty monetization strategy, noted an H.C. Wainwright & Co. report.


Survey Results Positive for New HAE Drug (11/02/2023)

Most responding physicians, all with hereditary angioedema patients, indicated an "above average" impression of the treatment's safety and efficacy data, noted an Oppenheimer report.


Safety Profile of New IL-2 Molecule Better Than Like Drugs' (11/02/2023)

First clinical data of this investigational interleukin-2 cytokine show it lacks the degree and rates of adverse events typically seen with treatments of this kind, noted an H.C. Wainwright & Co. report.


Firm To Present Trial Results Update at SITC Meeting (11/02/2023)

Data will be reviewed from Part B, the dose expansion portion, of the Phase 1 study of a new TGF-β1 isoform inhibitor in advanced cancer, noted a Wedbush report.


Add Back Positions in This Biotech (11/01/2023)

Chris Temple of The National Investor shares one stock he believes is currently a Buy, as a gross overreaction caused sell-offs.


More Archives

2024Jun May Apr Mar Feb Jan

2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes